Skip to main
ETON
ETON logo

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals Inc is positioned for significant revenue growth, with projections indicating that revenues associated with the Khindivi product will escalate to a peak of $28 million by 2030, up from just $3 million in 2025. The recent approval of Khindivi has led to an increase in the probability of its launch to 100% and an anticipated market penetration of 60%, highlighting a strong momentum in commercial execution. These factors, combined with a favorable timeline for market entry, suggest that 2025 could mark an important inflection point in the company’s revenue trajectory.

Bears say

Eton Pharmaceuticals's financial outlook reflects concerns regarding its current valuation, supported by an 11% discount rate and a modest 2% terminal growth rate, which suggest limited growth potential. The adjustments to the 12-month price target, increasing from $33 to $35 per diluted share, indicate a cautious optimism but still suggest underlying challenges that may prevent significant upward momentum. These factors collectively contribute to a negative sentiment surrounding the stock, highlighting the need for improved performance and market confidence to justify the current valuation.

ETON has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 3 analysts, ETON has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.